Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Perrigo Company PLC    PRGO   IE00BGH1M568

PERRIGO COMPANY PLC (PRGO)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/14/2019 01/15/2019 01/16/2019 01/17/2019 01/18/2019 Date
45.72(c) 45.2(c) 44.52(c) 44.87(c) 45.97(c) Last
1 216 836 1 331 123 1 499 290 1 321 180 1 404 077 Volume
+0.84% -1.14% -1.50% +0.79% +2.45% Change
More quotes
Financials (USD)
Sales 2018 4 716 M
EBIT 2018 904 M
Net income 2018 131 M
Debt 2018 2 721 M
Yield 2018 1,67%
Sales 2019 4 782 M
EBIT 2019 928 M
Net income 2019 356 M
Debt 2019 2 426 M
Yield 2019 1,70%
P/E ratio 2018 28,15
P/E ratio 2019 16,42
EV / Sales2018 1,90x
EV / Sales2019 1,81x
Capitalization 6 245 M
More Financials
Company
Perrigo Company PLC (Perrigo), formerly Perrigo Company Limited, is an over-the-counter (OTC) consumer goods and specialty pharmaceutical company. The Company's segments include Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx) and Specialty Sciences.... 
Sector
Pharmaceuticals
Calendar
02/14Earnings Release
More about the company
Surperformance© ratings of Perrigo Company PLC
Trading Rating : Investor Rating :
More Ratings
Latest news on PERRIGO COMPANY PLC
01/16GLANCY PRONGAY & MURRAY LLP : Reminds Investors of the Deadline in the Class Act..
BU
01/16PERRIGO : Initial filing by director officer or owner of more than ten percent.
PU
01/16PERRIGO : Appoints James Dillard to Role of Chief Scientific Officer
AQ
01/14PERRIGO Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceedi..
BU
01/14PERRIGO : Appoints James Dillard To Role Of Chief Scientific Officer
PR
01/10PERRIGO Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceedi..
PR
01/10DEADLINE REMINDER : The Law Offices of Howard G. Smith Reminds Investors of Loom..
BU
01/10IMPORTANT INVESTOR REMINDER : The Schall Law Firm Announces the Filing of a Clas..
BU
01/09PERRIGO : Glancy Prongay & Murray LLP Announces the Filing of a Securities Class..
BU
01/09The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Pe..
BU
More news
Analyst Recommendations on PERRIGO COMPANY PLC
More recommendations
Sector news : Pharmaceuticals - NEC
03:16aPHILIP HAMPTON : GSK Chairman Hampton to step down ahead of split
RE
03:12aGSK Chairman Hampton to step down ahead of split
RE
02:25aGlaxoSmithKline Chairman Philip Hampton to Step Down
DJ
01/18ELI LILLY AND : Lilly Reports Favorable Cyramza Results in Phase 3 Liver Cancer ..
DJ
01/18ABBVIE : Says Imbruvica Didn't Meet Endpoints in Pancreatic Cancer Study
DJ
More sector news : Pharmaceuticals - NEC
Chart PERRIGO COMPANY PLC
Duration : Period :
Perrigo Company PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PERRIGO COMPANY PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Average target price 67,8 $
Spread / Average Target 48%
EPS Revisions
Managers
NameTitle
Murray S. Kessler President, Chief Executive Officer & Director
Rolf Allan Classon Chairman
Ronald Janish Executive VP-Global Operations and Supply Chain
Ron L. Winowiecki Chief Financial Officer
Thomas Farrington Chief Information Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
PERRIGO COMPANY PLC18.63%6 245
JOHNSON & JOHNSON1.27%350 508
PFIZER-2.57%246 674
NOVARTIS5.66%227 840
ROCHE HOLDING LTD.6.16%223 498
MERCK AND COMPANY-0.71%197 291